Overview
Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with mAb114. The most common adverse events (incidence ≥ 20%) are pyrexia, chills, tachycardia, tachypnoea and vomiting. The rate of infusion of mAb114 may be slowed or interrupted if the patient develops any signs of infusion associated events.